CXCL9, CXCL-10, and CXCL-11 are mainly secreted by monocytes, endothelial cells, fibroblasts, and cancer cells in response to IFN-γ, which are synergistically enhanced by TNF-alpha while CXCR3, a common receptor of CXCL9/10/11, is preferentially expressed on the surface of monocytes, T cells, NK cells, dendritic cells, and cancer cells [30]. The gene discussed is IFNG; the disease is cancer.